Lojaimiess Kit
Product Images NDC 70700-207

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Lojaimiess (NDC 70700-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (50bc7836 Dbb6 439f 83b3 88f1f8758fc5 01)

This information appears to be related to a study or data analysis concerning menstrual cycles and bleeding or spotting. The text includes figures related to the duration of cycles, ranging from 27 days to 220 days, as well as percentages of women experiencing bleeding or spotting. Additionally, there are references to different cycles and the number of participants in each cycle. This data could potentially be used to analyze patterns or outcomes related to menstrual health.*

FDA Label Image

Structure (50bc7836 Dbb6 439f 83b3 88f1f8758fc5 02)

Levonorgestrel is a chemical compound with a molecular formula of C21H28O2 and a molecular weight of 312.4 g/mol. It is commonly used in birth control pills and emergency contraception.*

FDA Label Image

Structure (50bc7836 Dbb6 439f 83b3 88f1f8758fc5 03)

This is not readable.*

FDA Label Image

Levonorgestrel And Ethinyl Estradiol Tablets, Usp (0.1 mg/ 0.02 mg) And Ethinyl Estradiol Tablets, Usp (0.01 mg) Carton Label (Image 01)

The text contains information about two types of tablets, Levonorgestrel and Ethinyl Estradiol, in different dosages of 0.1mg/0.02mg and 0.01mg. The tablets are packaged in extended-cycle blister packs. The first type has the NDC number 7070020733 and the second type has NDC number 7670020753. This information seems to pertain to pharmaceutical products.*

FDA Label Image

Image (Image 02)

This text provides information about different methods of birth control and their effectiveness in preventing pregnancies. It lists various options, such as implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal rings with hormones, condoms, diaphragm, avoiding sex during fertile days, spermicide, withdrawal, and the concept of no birth control leading to pregnancies. It also categorizes the effectiveness of birth control methods based on the number of pregnancies per 100 women in one year.*

FDA Label Image

Blister (Image 03)

FDA Label Image

Figure 3: Relevant Studies Of Risk Of Breast Cancer With Combined Oral Contraceptives (Image 04)

This text provides information on relevant studies evaluating the risk of breast cancer with combined oral contraceptives (COC). It includes comparisons of Ever COC vs. Never COC Use as well as Current COC use vs. Never-Use, showcasing data from studies such as the NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, The Nurses' Health Study, and the Oxford Family Planning Study among others. Different effect estimates such as Relative Risk (RR), Odds Ratio (OR), and Hazard Ratio (HR) are used to analyze the risk.*

FDA Label Image

Figure 1: Likelihood Of Developing A Vte (Image 05)

This text provides information on the risk of developing a blood clot for various groups of women such as non-pregnant, non-COC (Combined Oral Contraceptive) users, COC users, pregnant women, and postpartum women. The data includes ranges of blood clot occurrences per 10,000 Women Years (WY) for each group. It also mentions that the pregnancy data is based on actual pregnancy duration, with a calculated rate of 7 to 27 blood clots per 10,000 WY.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.